For medical device manufacturers operating across international markets, 2026 has arrived with a level of regulatory complexity that makes a coherent global compliance strategy more important than ever. The CE mark, long treated as a de facto global passport for device market access, is facing structural challenges in several key markets simultaneously. At the same time, national approval frameworks in the United States, United Kingdom, Australia, Japan, and other major markets are each evolving on independent timelines, creating a landscape where the cost, sequencing, and strategic logic of device approval decisions can have significant consequences for commercial timelines and compliance resource allocation.
This guide is written for quality, regulatory affairs, and compliance teams at medical device manufacturers who need a clear picture of where things stand globally in 2026 and what decisions they need to be making now to protect their market access and manage their compliance programmes effectively.
Read More: How to Respond to a Regulatory Deficiency Letter: A Step-by-Step CAPA Guide for Pharmaceutical Sites
Understanding the CE Mark in 2026: Stronger but More Demanding
The CE mark under the EU Medical Device Regulation 2017/745 and the EU In Vitro Diagnostic Regulation 2017/746 remains the most widely recognised device approval framework globally. However, the transition from the legacy Medical Device Directive to the full EU MDR has fundamentally changed what the CE mark requires and how difficult it is to obtain and maintain.
The EU MDR introduced substantially higher pre-market clinical evidence requirements, more demanding post-market clinical follow-up obligations, stricter requirements for the content and currency of technical documentation, and a more rigorous notified body assessment process. The transition has caused significant disruption across the industry, with notified body capacity constraints delaying assessments for many manufacturers and a number of smaller device companies withdrawing products from the EU market entirely rather than bearing the cost of MDR compliance.
The key changes under EU MDR that continue to affect manufacturers in 2026 include:
- Stricter clinical evidence requirements that in most cases cannot be met by equivalence claims alone, requiring manufacturers to generate device-specific clinical data
- More detailed and frequently updated technical documentation requirements including updated clinical evaluation reports and post-market clinical follow-up plans
- Enhanced unique device identification requirements and mandatory registration on the EUDAMED database, which is now progressively becoming operational
- Stricter obligations for post-market surveillance, periodic safety update reports, and summary of safety and clinical performance documents for higher risk devices
- Notified body oversight that is substantially more intensive than under the previous MDD framework, with more frequent surveillance audits and unannounced facility visits
For manufacturers who achieved MDD certification and are now transitioning to EU MDR, the residual transitional arrangements that have been extended several times are approaching their final deadlines. The current transitional period for MDD-certified devices runs until 31 December 2028 under EU timelines, and manufacturers should treat this as a hard deadline that will not be extended further given the political appetite within the EU for full MDR implementation.
The UK Market in 2026: A Pivotal Regulatory Moment
The United Kingdom represents one of the most significant regulatory developments for device manufacturers in 2026. Following Brexit, the UK introduced the UKCA mark as the Great Britain equivalent of the CE mark. However, the mandatory requirement for UKCA marking has been repeatedly deferred as the government recognised that requiring full UKCA certification would risk supply disruption for the approximately 90 percent of medical devices currently used in Great Britain that carry CE marking.
In February 2026, the MHRA launched a public consultation on proposals that would fundamentally reshape this situation. The proposals put forward include:
- Indefinite recognition of devices certified under the EU MDR and EU IVDR in Great Britain, removing the need for separate UKCA conformity assessment for these devices
- Extension of transitional arrangements for MDD-compliant devices to align with the EU timeline of 31 December 2028
- Introduction of an international reliance route for devices that fall into a higher risk classification under UK rules than under EU rules, where a UK approved body would conduct a streamlined review rather than a full independent assessment
If the indefinite recognition proposal is adopted, it would represent a fundamental change in the strategic calculation for device manufacturers planning their UK market access. Under this model, achieving and maintaining EU MDR certification would effectively also secure Great Britain market access without the additional cost and administrative burden of a separate UKCA process. Manufacturers would still need to register their devices with the MHRA and comply with UK post-market surveillance requirements but the conformity assessment duplication that has been a source of significant industry concern would be largely eliminated.
The consultation closed in April 2026 and the outcome is expected to be reflected in a statutory instrument later in 2026. Manufacturers planning their regulatory strategy for the UK market should monitor this development closely and avoid making irreversible investment decisions around UKCA certification until the policy direction is confirmed.
The United States: FDA 510(k), De Novo and PMA in the Current Environment
For manufacturers supplying the US market, the FDA device approval framework operates entirely independently of the CE mark, and the two systems have limited formal recognition of each other despite ongoing regulatory cooperation between the FDA and international partners.
The three primary pathways for device market access in the United States remain the 510(k) premarket notification for devices substantially equivalent to a predicate, the De Novo classification request for novel lower-risk devices without a suitable predicate, and the Premarket Approval process for high-risk Class III devices requiring clinical evidence of safety and effectiveness.
In 2026 the FDA continues to place increasing scrutiny on the quality of 510(k) submissions, particularly the robustness of substantial equivalence arguments and the adequacy of performance testing data. The agency has been explicit in recent guidance documents that it expects performance testing to reflect current state-of-the-art standards and that substantial equivalence arguments relying on older predicates with outdated design or performance characteristics will receive increased scrutiny.
Key considerations for manufacturers planning US market access in 2026 include:
- The FDA has updated its guidance on the use of real-world evidence to support device approvals and post-market decisions, opening pathways for manufacturers with robust post-market data to supplement pre-market submissions
- Software as a Medical Device continues to be an area of intensive regulatory development, with the FDA, EMA, and MHRA each developing updated frameworks for AI and machine learning enabled devices that are not yet fully harmonised
- The FDA’s Quality System Regulation has been updated and aligned more closely with ISO 13485:2016, which reduces but does not eliminate the differences between quality management system requirements for the US market and those required for CE marking
- Post-market surveillance expectations are increasing in line with international trends, with the FDA placing greater emphasis on the adequacy of post-market study designs and the timeliness of safety reporting under the Medical Device Reporting regulation
One important strategic consideration for manufacturers holding both CE marks and FDA clearances is that clinical data generated for EU MDR compliance purposes, particularly post-market clinical follow-up data, is increasingly being accepted by the FDA as supporting evidence in post-market submissions and in some cases as supplementary evidence in pre-market applications. Building a clinical evidence programme that serves multiple regulatory submissions simultaneously is a significant efficiency opportunity that many manufacturers are not yet fully exploiting.
Australia, Japan and Other Major Markets: The Reliance Trend
Beyond the EU, UK, and US, the regulatory landscape for medical devices is increasingly shaped by a trend toward international reliance, where national regulatory authorities formally rely on the assessments of other trusted reference regulators rather than conducting fully independent reviews.
In Australia, the TGA has developed a reliance pathway that allows manufacturers holding approvals from recognised comparable overseas regulators including the FDA, EMA member state authorities, and Health Canada to apply for Australian market inclusion based on the reference approval. This significantly reduces the assessment burden for manufacturers who have already achieved approval in a primary market, though TGA-specific requirements around labelling, post-market obligations, and mandatory reporting still apply.
In Japan, the PMDA operates a more complex approval environment that historically required significant Japan-specific clinical data, but recent reforms as part of Japan’s regulatory modernisation programme have introduced greater flexibility for manufacturers with strong international approval histories. Manufacturers planning Japan market entry should factor in the PMDA’s specific expectations around Japanese language labelling, localised post-market surveillance plans, and the involvement of a local marketing authorisation holder.
Health Canada in Canada has also been developing reliance frameworks that draw on FDA and EU approvals, and the International Medical Device Regulators Forum continues to work toward greater convergence of regulatory requirements across its member authorities, which include most of the world’s major device regulatory agencies.
The practical implication for manufacturers planning a global market access strategy is that the sequence in which you pursue approvals matters enormously. Achieving EU MDR CE certification and FDA clearance or approval first, before pursuing secondary markets, maximises the reliance opportunities available in markets like Australia, Canada, and increasingly Japan. Building your clinical evidence, quality management system, and post-market surveillance programme to the standard required by the most demanding reference regulators from the outset avoids the need to retrofit your compliance programme for secondary markets later.
Building a Global Compliance Strategy: The Key Decisions for 2026
Given the complexity of the landscape described above, manufacturers need to approach their global compliance strategy as a deliberate planning exercise rather than a reactive response to individual market requirements. The decisions made in 2026 about which markets to prioritise, which approval sequences to follow, and how to structure the clinical and quality evidence programmes will shape compliance costs and market access timelines for years.
The strategic questions every device manufacturer should be working through in 2026 are:
- Which markets represent your primary commercial priority and which regulatory pathways in those markets are most efficiently sequenced given your current approval status
- Whether your technical documentation, clinical evaluation, and post-market surveillance programme is built to EU MDR standards, which remain the most demanding pre-market evidence requirements globally and therefore the most transferable
- How the expected outcome of the MHRA’s CE mark recognition consultation should influence your investment decisions around UKCA certification
- Whether your quality management system is certified to ISO 13485:2016 with the scope and design necessary to support both CE marking and FDA QSR compliance simultaneously
- How your post-market clinical follow-up programme can be designed to generate evidence that serves multiple regulatory submissions rather than being designed narrowly for a single market
- Whether your unique device identification and EUDAMED registration programme is on track to meet EU obligations given the progressive activation of EUDAMED modules
How Quality and Vigilance Supports Global Device Compliance Strategies
At Quality and Vigilance, we work with medical device manufacturers navigating the full complexity of global regulatory compliance across EU MDR, MHRA, FDA, TGA, and other international frameworks. Our team understands the practical realities of building compliance programmes that work across multiple markets simultaneously, including the sequencing decisions, the clinical evidence challenges, and the post-market surveillance obligations that each framework imposes.
We support device manufacturers with regulatory strategy development, technical documentation review and gap assessment against EU MDR requirements, post-market surveillance and PMCF plan development, quality management system gap assessment against ISO 13485 and FDA QSR requirements, and preparation for notified body audits and regulatory inspections across multiple jurisdictions.
Our approach is always grounded in the practical commercial and operational context of each manufacturer we work with. A compliance strategy that looks rigorous on paper but cannot be implemented within your operational and financial reality will not serve your business or your patients. We build strategies that are both regulatorily robust and operationally achievable.
Contact Quality and Vigilance today to discuss your global device compliance strategy and find out how our team can help you navigate the regulatory landscape of 2026 and beyond with confidence.